Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐CD20 monoclonal antibody for the desensitization of candidates for renal transplant
暂无分享，去创建一个
R. Redfield | E. Reed | A. Zachary | S. Busque | R. Formica | E. Woodle | F. Vincenti | S. Jordan | E. Woodle | S. Tremblay | P. Brunetta | C. Green | N. Desai | M. Cascino | T. Schindler | C. Jamois | A. Vo | D. Borie | R. Rajwanshi | A. Morimoto | H. Tran | C. Looney | Aaron Schroeder | Cherie Green | Stanley C. Jordan | R. R. Redfield | Elaine F. Reed